Drug intelligence / Profile preview

Liposic EDO Gel

Development stage: Unknown
Lead developer: Bausch + Lomb
Modality: Small Molecules
Administration: Ophthalmic

Overview

Liposic EDO Gel is a preservative-free, carbomer-based ophthalmic gel containing lipids (medium-chain triglycerides) designed for the symptomatic treatment of dry eye disease. Developed by Bausch + Lomb, it acts as a tear film substitute and lubricant. The carbomer component increases the viscosity of the tear film, while the lipid component helps stabilize the lipid layer of the tear film, reducing evaporation. It is specifically formulated as a single-dose (EDO) product to avoid preservatives, making it suitable for patients with sensitive eyes or severe dry eye syndrome requiring frequent application.

Brand names: Liposic EDO Gel
Other names: carbomer 980 gelcarbomer980 gelcarbomer-980 gelcarbomer-based lipid-containing artificial tearCBLAT

Beyond the preview

Go deeper on Liposic EDO Gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liposic EDO Gel.

Explore the full profile